Literature DB >> 35604531

Clinical value of 18F-FDG PET/CT in IgG4-related disease.

Zhiqian Bai1, Tianshu Zhou1, Zhihua Yu2, Yu Chen3, Lingli Dong4.   

Abstract

OBJECTIVE: To investigate the clinical value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in IgG4-related disease (IgG4-RD).
METHODS: Seventy two patients diagnosed with IgG4-RD who underwent PET/CT were included. Correlations between clinical variables and PET/CT findings were analyzed by Spearman's correlation test. Conventional radiology was compared to PET/CT to evaluate detection discrepancies. The detection ability of insidious organ involvement by PET/CT at disease onset was investigated. The utility value of PET/CT for the 2019 ACR/EULAR classification criteria was analyzed with the multivariate logistic analysis and ROC curve.
RESULTS: SUVmax of main involved organ was positively correlated with IgG4-RD Responder Index (IgG4-RD RI), serum and tissue IgG4 levels and IgG4/IgG ratio, serum eosinophils counts and number of involved organs, while negatively correlated with serum IgM levels. PET/CT was superior in detecting organ/tissue involvements including prostate, gastrointestinal tract and lung compared with conventional imaging. For patients with pancreato-hepato-biliary or head-neck involvements at onset, PET/CT showed superiority in detecting insidious lesions. Multivariate analysis showed that disease duration, multiple-organ involvement, SUVmax of main involved organ and mean SUVmax of all involved organs were significantly associated with the fulfillment of the 2019 ACR/EULAR classification criteria. ROC curves indicated that the cut-off value for SUVmax of main involved organ and mean SUVmax of all involved organs for fulfillment of the 2019 ACR/EULAR classification criteria for IgG4-RD were 4.1 and 3.5, respectively.
CONCLUSION: 18F-FDG PET/CT has potential capacity to monitor disease activity, evaluate organ involvements and assist in the classification criteria in IgG4-RD.
© 2022. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.

Entities:  

Keywords:  18F-FDG PET/CT; Diagnosis; IgG4-related disease; Organ involvements; The 2019 ACR/EULAR classification criteria

Mesh:

Substances:

Year:  2022        PMID: 35604531     DOI: 10.1007/s12149-022-01749-1

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  2 in total

1.  ¹⁸F-FDG PET-CT usefulness in extra-pancreatic involvement in IgG4 related diseases.

Authors:  R Cárdenas-Perilla; J Monturiol-Duran; M Simó-Perdigó; M Barios-Profitós; J Castell-Conesa
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2014-03-12       Impact factor: 1.359

2.  Development and validation of a nomogram to estimate the risk of prostate cancer in Brazil.

Authors:  Thiago B Silva; Cleyton Z Oliveira; Eliney F Faria; Edmundo C Mauad; Kari J Syrjänen; André L Carvalho
Journal:  Anticancer Res       Date:  2015-05       Impact factor: 2.480

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.